Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Just got my helium mobile service activated. It was simple to get things going through their app. They assigned me a phone number based off of my home address. They let you pay with Google pay or a credit or debit card. The activation was simple. For devices with e-sim it is even easier as they do not require a sim card to be mailed. The phone must be unlocked prior to activation.
Got my Helium Mobile Sim card delivered today from Amazon. I'll try it out in my unlocked phone tomorrow.
Helium Mobile launches group plans!
https://www.fierce-network.com/wireless/helium-mobile-makes-another-move-disrupt-wireless-20line-group-plans
Nice green weekend action!
$mobile
Made it to the top gainers list for Crypto.com
$Mobile!
Wow I am liking the movement today! Green!
Things are looking good for Helium Mobile. They are just about to launch a new market in LA. This will eventually grow and get even better.
All I see is green now
Looks like I donated my money to a black hole. The bottom just keeps getting lower.
Everything follows bitcoin. With the threat of inflation and the lower incentives to bitcoin mine. This leaves great uncertainty for many in the market. The trend also seems to follow bad days in the stock market which was extremely red today. Maybe it's a good time to buy if you have liquid funds.
I chose between mobile and limewire. This one lost 33% and the other one doubled. Well I will continue to wait.
I thought this hit bottom but it's been trending down for a week now. I feel it's being manipulated to go back down so some whale can push it back up again. Still waiting. Buying and holding now.
I got a golden ticket
Starting to see some action. With Bitcoin up this may see a bump here.
Time for the launch. READY GO
I think it just hit bottom. It seems to follow Bitcoin closely. When bitcoin goes back up this will shoot up. Potential of 2x at these prices.
I say this is primed to move up soon. It's a perfect time to load and seems to be holding strong at these levels.
SHIB is going for a nice run. Could see 100% gains off the low.
Still wild to see this actually trading. There must be a lot of bag holders out there just waiting for this moment.
FyI the company no longer exists and they don't have any products. There is no Financials. Just an empty shell full of bagholders waiting for their next victim.
Even during a pandemic people still need phones. People probably use their phone more than ever. I would consider buying this after the 4>1 split goes through. Maybe a week after it settles same thing happened to Netflix. It went back to the original amount within 2 years. Wait on the buy for a week or 2
He moved to Columbia and just had a baby with his young girlfriend. He is no longer involved with this business. Basically it is an empty shell with no business
CNS Pharmaceuticals Entered $2.0 Million Sublicense Agreement with WPD Pharmaceuticals
Download as PDFNOVEMBER 26, 2019 8:00AM EST
HOUSTON, Nov. 26, 2019 /PRNewswire/ -- CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("Company"), a biotechnology company specializing in the development of novel treatments for brain tumors, entered into a sublicense agreement with WPD Pharmaceuticals ("WPD"), a Polish corporation partially owned and controlled by Dr. Waldemar Priebe, the founder of the Company. The agreement grants WPD patent rights to research and develop, and manufacture or sell Berubicin in a limited territory comprised mainly of Eastern Europe and Central Asia. The Company is entitled to a 1% royalty on all commercial sales of Berubicin in these licensed territories.
As part of the agreement, WPD committed to a $2.0 million minimum expenditure on the development, testing, regulatory approval, and commercialization of Berubicin during the three year term of the agreement, which ends in August 2021. WPD plans to implement a multicenter pediatric Phase I clinical trial to determine maximum tolerated dose, and to determine the efficacy of Berubicin in Phase IB and II clinical trials in adults. WPD also plans to conduct preclinical tests to determine the prospective use of Berubicin with temozolomide and with other compounds as anticancer drugs.
"We were extremely excited to enter into an agreement with WPD and to further explore the potential of Berubicin as an anthracycline internationally," commented CEO of CNS, John M. Climaco. "Our agreement with WPD is truly a testament to our unrelenting commitment to pursuing treatments for glioblastoma around the world."
CNS Pharmaceuticals Filed Request with FDA for Pre-IND Meeting for Berubicin
Download as PDFNOVEMBER 21, 2019 8:00AM EST
HOUSTON, Nov. 21, 2019 /PRNewswire/ -- CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("Company"), a biotechnology company specializing in the development of novel treatments for brain tumors, filed a Pre-IND meeting request for Berubicin for IV for the Treatment of Glioblastoma Multiforme to the US Food and Drug Administration Division of Oncology Products 2, Center for Drug Evaluation and Research.
In its request, the Company outlined its rationale for the continued investigation of the compound and detailed key questions for the FDA, including its permission to utilize the supply of Berubicin acquired from Reata Pharmaceuticals Inc. in the planned upcoming Phase II clinical trial. The company has performed a preliminary purity testing and analysis on Reata's supply of Berubicin and verified that it is 99.9% pure.
"We believe that utilizing the supply of Berubicin we acquired from Reata could offer the Company significant costs savings and eliminate the excess risk and time associated with manufacturing complex drugs," stated CEO of CNS, John M. Climaco.
News just out: CNS Pharmaceuticals Acquired Worldwide Rights for Brain Cancer Drug from Houston Pharmaceuticals
Download as PDFNOVEMBER 19, 2019 8:00AM EST
HOUSTON, Nov. 19, 2019 /PRNewswire/ -- CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("Company"), a biotechnology company specializing in the development of novel treatments for brain tumors, completed an agreement with Houston Pharmaceuticals, Inc. ("HPI") to obtain the rights to a worldwide, exclusive royalty-bearing, license for the chemical compound commonly known as Berubicin.
CNS' licensing agreement with HPI grants the Company the exclusive right to develop certain patented chemical compounds for use in the treatment of cancer globally. In its agreement with HPI, the Company acquired multiple U.S. patents for Berubicin. CNS intends to apply for orphan drug status for Berubicin with the FDA for the treatment of malignant glioma.
"We believe our acquisition of the rights to Berubicin represents an important milestone in our pursuit to develop therapies for the treatment of glioblastoma, a type of brain cancer which is currently considered incurable," stated CEO of CNS, John M. Climaco, Esq. "Our agreement with HPI expands our IP protection and provides us with developmental protection worldwide while we seek orphan drug status. We are excited to continue the clinical development of Berubicin and believe its promising tolerability and efficacy results are a testament to its therapeutic potential as a novel anthracycline agent."
CNSP wow look at all the premarket buys. Today is going to be a good day!
CNSP looking forward to another week of green. Target $5.00 and beyond this week.
$CNSP is starting to run again. Things have thinned out.
$CNSP breaking out now. Things are thin and moving.
$CNSP starting off green again. Things are moving slow but still green! Everyone is waiting on the next big announcement from the company.
$CNSP having a nice green day. On the verge of a large breakout.
$CNSP is starting to break out. Resistance is thing. This really could move. The company is no longer selling shares. This could be huge.
$CNSP breakout in progress. Check it out.
$CNSP having a very nice green day today.
$CNSP more news just out 8K is now filed. A new CFO has been hired.
https://www.sec.gov/Archives/edgar/data/1729427/000168316819003575/cns_8k.htm
$CNSP potential break out tomorrow with news after hours. This is a new IPO and have just completed selling shares.
CNS Pharmaceuticals Announces Closing Of Initial Public Offering of Common Stock
Source: PR Newswire (US)
HOUSTON, Nov. 13, 2019 /PRNewswire/ -- CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("Company"), a pre-clinical stage biotechnology company specializing in the development of novel treatments for brain tumors, today announced the closing of its initial public offering of 2,125,000 shares of common stock at an initial public offering price of $4.00 per share. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by the Company, were $8.5 million.
$CNSP just launched IPO last Friday and announced some news after hours. Might be a big green day tomorrow.
CNS Pharmaceuticals Announces Closing Of Initial Public Offering of Common Stock
Source: PR Newswire (US)
HOUSTON, Nov. 13, 2019 /PRNewswire/ -- CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("Company"), a pre-clinical stage biotechnology company specializing in the development of novel treatments for brain tumors, today announced the closing of its initial public offering of 2,125,000 shares of common stock at an initial public offering price of $4.00 per share. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by the Company, were $8.5 million.
$CNSP just launched IPO last Friday and is now done selling shares. Tomorrow is going to be a big green day. News was announced after hours.
CNS Pharmaceuticals Announces Closing Of Initial Public Offering of Common Stock
Source: PR Newswire (US)
HOUSTON, Nov. 13, 2019 /PRNewswire/ -- CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("Company"), a pre-clinical stage biotechnology company specializing in the development of novel treatments for brain tumors, today announced the closing of its initial public offering of 2,125,000 shares of common stock at an initial public offering price of $4.00 per share. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by the Company, were $8.5 million.
Gonna be a big green day tomorrow. The dilution is over and time to run.
CNS Pharmaceuticals Announces Closing Of Initial Public Offering of Common Stock
Source: PR Newswire (US)
HOUSTON, Nov. 13, 2019 /PRNewswire/ -- CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("Company"), a pre-clinical stage biotechnology company specializing in the development of novel treatments for brain tumors, today announced the closing of its initial public offering of 2,125,000 shares of common stock at an initial public offering price of $4.00 per share. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by the Company, were $8.5 million. In addition, the Company has granted the underwriters a 45-day option to purchase up to an additional 318,750 shares of common stock at the initial price to the public less underwriting discounts and commissions. The Company's common stock is listed on the NASDAQ Capital Market under the symbol CNSP.
The Benchmark Company, LLC acted as sole Book Running Manager for the offering.
A registration statement on Form S-1 (File No. 333-232443) relating to the shares was filed with the Securities and Exchange Commission ("SEC") and became effective on November 7, 2019. The offering was made only by means of a prospectus. Copies of the final prospectus may be obtained from The Benchmark Company, LLC, Attn: Prospectus Department, 150 E 58th Street, 17th floor, New York, NY 10155, 212-312-6700, Email: prospectus@benchmarkcompany.com.
This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Berubicin
Berubicin is an anthracycline, a class of drugs among the most powerful chemotherapy drugs and effective against more types of cancer than any other class of chemotherapeutic agents. Anthracyclines are designed to damage the DNA of targeted cancer cells by interfering with the action of the topoisomerase II, a critical enzyme enabling cell proliferation. Berubicin was developed at the MD Anderson Cancer Center (MDACC), the world's largest cancer research facility. Berubicin appeared to demonstrate one Durable Complete Response in a Phase I human clinical trial conducted by a prior developer.
About CNS Pharmaceuticals, Inc.
CNS Pharmaceuticals is a pre-clinical stage biotechnology company specializing in the development of novel treatments for primary and metastatic brain and central nervous system tumors. Its lead candidate Berubicin is for the treatment of glioblastoma, a type of brain cancer currently considered incurable, as well as pancreatic and ovarian cancers, and lymphonas. The Company entered into an IP agreement with Houston Pharmaceuticals, Inc. and a Purchase Agreement with Reata Pharmaceuticals Inc. For more information, visit www.cnspharma.com
Investor Relations Contact
James Salierno / Kait Brosco
The Ruth Group
646-536-7000
jsalierno@theruthgroup.com
kbrosco@theruthgroup.com
Media Contact
Kirsten Thomas
The Ruth Group
(508) 280-6592
kthomas@theruthgroup.com
? View original content:http://www.prnewswire.com/news-releases/cns-pharmaceuticals-announces-closing-of-initial-public-offering-of-common-stock-300957850.html
SOURCE CNS Pharmaceuticals, Inc.
?
Copyright 2019 PR Newswire
Wow look at all the action today. It's gonna be a nice green day.